AP NEWS

New Data Show LEO Pharma’s Kyntheum® (brodalumab) Provides Greater Probability of Achieving Complete Skin Clearance for People with Moderate to Severe Psoriasis Compared with ustekinumab

September 13, 2018

BALLERUP, Denmark--(BUSINESS WIRE)--Sep 13, 2018--Data presented at the 27 th European Academy of Dermatology and Venereology (EADV) in Paris, show that treatment with LEO Pharma’s Kyntheum ® (brodalumab) for people with moderate to severe plaque psoriasis, was associated with a more rapid reduction in absolute Psoriasis Area Severity Index (PASI) scores and a greater probability of achieving complete skin clearance in all body regions compared with ustekinumab. 1,2 The possibility of attaining completely clear skin makes a significant difference to the lives of people with psoriasis, according to the newly published PsoClear Report. 3

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180913005057/en/

Outcomes of the first of two analyses of pooled data from the AMAGINE-2 and AMAGINE-3 studies showed a greater proportion of those taking Kyntheum ® achieved (absolute) PASI 0, meaning complete skin clearance without any symptoms of psoriasis, over time compared with ustekinumab (75% versus 52%, respectively at 52 weeks). 1 Absolute PASI scores measure the severity of redness, thickness and scaling of skin on different parts of the body, whereby a score of less than three is indicative of treatment success. 4 Results of the second analysis found that the time it took for 50% of patients to achieve complete clearance across all body regions – head and neck, trunk, upper limbs and lower limbs – was shorter with Kyntheum ® than ustekinumab. Over the course of the 52-week analysis, superior rates of complete clearance were seen as early as week two for Kyntheum ® treated patients. 2Please see the full press release attached.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180913005057/en/

CONTACT: LEO Pharma A/S

Henrik Kyndlev

henrik.kyndlev@leo-pharma.com

Tel. +45 3140 6180

KEYWORD: EUROPE DENMARK

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: LEO Pharma

Copyright Business Wire 2018.

PUB: 09/13/2018 03:00 AM/DISC: 09/13/2018 03:01 AM

http://www.businesswire.com/news/home/20180913005057/en

AP RADIO
Update hourly